Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

• Главные авторы: Tais Basaco (Автор), Stefanie Pektor (Автор), Josue M. Bermudez (Автор), Niurka Meneses (Автор), Manfred Heller (Автор), José A. Galván (Автор), Kayluz F. Boligán (Автор), Stefan Schürch (Автор), Stephan von Gunten (Автор), Andreas Türler (Автор), Matthias Miederer (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2018-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with ¹⁷⁷Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization...